Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars ‘Policy Salad’ Setting Back Sector, Canadian Study Says

Biosimilar Use Across Canada Remains Low

Executive Summary

The Ontario Drug Policy Research Network has released a new study on biosimilar uptake across Canada, where the use of biosimilars is relatively low in comparison to other OECD countries.

You may also be interested in...



Nova Scotia Becomes Sixth Jurisdiction To Implement Biosimilar Switching

Citizens enrolled on Nova Scotia’s Pharmacare programs have 12 months to switch to biosimilar versions of certain biologic drugs, including some insulins and medications used to treat Crohn’s disease and rheumatoid arthritis. 

Canadian Paper Pushes Back On Biosimilar Switching

A joint position statement published by originator-backed bodies the Canadian Association of Gastroenterology and Crohn’s and Colitis Canada has expressed caution over so-called ‘non-medical switching’ of IBD patients from brand biologics to biosimilars.

Inflation Impact Must Be Considered During Generics Pricing, Says Canadian Study

Canadian provinces must consider the impact of inflation on generic drugs during the next round of off-patent price setting, says a study from Aviseo and the Canadian Generic Pharmaceutical Association.

Topics

UsernamePublicRestriction

Register

GB151839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel